A Phase 4 interventional study of Saline injection and PRP injection in Osteoarthritis (OA) of the Knee, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by National Taiwan University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.
Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 7th largest by planned enrollment, is one of 2 that started in 2018, is one of 7 in phase 4, and was the 16th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:
Goed Medisch Centrum · Sites in Netherlands
Ages 18+
University of Utah · Sites in United States
Ages 18+ · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–100
VivaTech International, Inc. · Sites in United States
Ages 18–90 · Healthy volunteers
University Hospital of North Norway · Sites in Norway
Ages 40–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6 · Phase 4 7
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 70 across the 28 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 28 have an industry lead sponsor. The 10 most frequent:
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
National Taiwan University Hospital has 9 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
2 of the studies testing platelet rich plasma in Osteoarthritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491302Goed Medisch CentrumThumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection | 2027-05 |
| NCT03734900National Taiwan University HospitalComparison of Effectiveness Between PL and PRP on Knee Osteoarthritis: a Prospective,Randomized,Placebo-controlled Trial | 2027-05-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing platelet rich plasma in Osteoarthritis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will focus on grade I to III knee osteoarthritis by randomized controlled trials which comparing the effectiveness between placebo, autologous platelet rich plasma and autologous platelet lysate injections.
The current methods for treating knee osteoarthritis include delaying the disease progression and joint replacement surgery. The usual treatment methods are mostly temporary, such as taking drug and hyaluronic acid injection. Therefore, finding the safe and effective methods will greatly reduce medical resource, medical expenses and surgery cost, etc., and restore the patient's quality of life. Platelet lysate is the product of complete activation from autologous platelet. It contains rich growth factors and cytokines such as PDGF, TGF-β, VEGF, EGF and IGF, etc. It can support cell growth and doesn't have any white blood cells in it. It is superior to the platelet rich plasma because of reducing the overall inflammatory response and pain of the patient during treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
Other: Saline injection
PRP injection into the study knee joint every 4 weeks for a total of 3 injections
Biological: PRP injection
PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
Biological: PL injection
5ml Placebo infusion of 0.9% Sodium Chloride
Device: "Aeon" Acti-PRP 5ml autologous platelet rich plasma injection
Device: "Aeon" Acti-PRP 5ml autologous platelet lysate injection
Pain score of the patient
Using Visual Analog Score (from 0 to 10, 0 indicate no pain and 10 indicate maximal pain) to evaluate pain of surgical wound of the patient
Time frame: up to 24 weeks after surgery
Knee functional score
Using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time frame: up to 24 weeks after surgery
X-ray
Knee X-ray image
Time frame: up to 24 weeks after surgery
Ultrasonic image
Ultrasonic-between thickness of the medial and lateral sides of the femoral condyle
Time frame: up to 24 weeks after surgery
adverse events
adverse events in clinical trial
Time frame: up to 24 weeks after surgery
Started May 2018 (actual). Primary completion is estimated for May 2027, 107 months after the start.
Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 107 months is above that.
Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma
National Taiwan University Hospital →